Design and characterization of a salicylic acid-inducible gene expression system for Jurkat cells
With continued progress in cell and gene therapies, there is an immediate need for exogenously tunable gene expression systems with safe and predictable behavior in specific human cell types. Here, we demonstrate the ability of the salicylic acid (SA)-inducible MarR repressor protein from Escherichi...
Gespeichert in:
Veröffentlicht in: | Journal of biotechnology 2022-02, Vol.346, p.11-14 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | With continued progress in cell and gene therapies, there is an immediate need for exogenously tunable gene expression systems with safe and predictable behavior in specific human cell types. Here, we demonstrate the ability of the salicylic acid (SA)-inducible MarR repressor protein from Escherichia coli to regulate target gene expression in a human T lymphocyte cell line. Two lentiviral vectors, one encoding an enhanced green fluorescent protein (EGFP) reporter cassette and the other a repressor cassette, were sequentially transduced into Jurkat cells, using fluorescence-activated cell sorting (FACS) to isolate stable Jurkat progeny. As a result, EGFP expression was repressed by MarR and was inducible upon the addition of SA (~1.3 fold). This represents the first example of functional expression of bacterial MarR in mammalian cells, and opens the possibility for further development of regulated, SA-tunable gene expression system for T-cells.
•Repressor protein MarR was repurposed for salicylic acid (SA)-inducible heterologous gene expression in human T-cells.•Lentiviral transduction was performed to integrate into Jurkat cells a marR gene fusion, under control of promoter PGK-1.•Expression of egfp under control of a promoter containing mar operators was regulated by varying the concentration of SA. |
---|---|
ISSN: | 0168-1656 1873-4863 |
DOI: | 10.1016/j.jbiotec.2022.01.003 |